Back to search results

Observational Study of Psychotropic Medications and Eye Movements

This study is looking at how long-term use of psychiatric medications (called psychotropic medications) affects eye movements. Researchers want to see if a special device called Gaize, which uses virtual reality, can accurately detect eye movement patterns in people who have been taking these medications for over three months. The study is open to adults aged 18 to 65 who are currently taking a prescribed psychiatric medication and have normal or corrected vision. The goal is to see if the Gaize device can identify eye movements that are linked to taking these medications, similar to how Drug Recognition Experts (DREs) assess substance use. This is an observational study, meaning researchers will be watching and collecting data, not giving new treatments. The study aims to enroll 50 participants, and its current status is unclear.

Study design
This is an observational study with a planned enrollment of 50 participants. It is not specified if it's randomized or blinded.
What's involved
You would participate for one day, during which ophthalmic (eye-related) data will be collected.
Compensation
Not stated in the trial record.
Follow-up
Your ophthalmic data will be collected at 1 Day, and no further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07389473

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

Recruiting
Not specifiedAges 18–65Observational
Gaize
~50 participants
Updated 2026-02-05 on ClinicalTrials.gov
What's tested:Prescription Psychotropic Medications

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Collection of Ophthalmic Data
Measured over 1 Day

Conditions

ADHD
Depression Disorders
Mood Disorders
Anxiety Disorder Generalized
Bipolar Disorder (BPD)

Explore related trials

Attention Deficit Hyperactivity DisorderBipolar DisorderDepressionGeneralized Anxiety DisorderMood Disorder

Where it's being run

1 sites across 1 states
Pennsylvania1

Who to contact

Apurva Raje Research Coordinator / Principal Investigator, BA
[email protected]
732-397-1795
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged between 18 and 65, having given written informed consent to participate in the research trial.
Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.
Normal or corrected to normal vision using either glasses or contact lenses, or surgery.

Exclusion

Enrolled in, or participated in another clinical trial within 30 days before the study
Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days.
Had your eyes dilated by a medical doctor in the previous 24 hours.
Photosensitive epilepsy
Diagnosed with clinical blindness
Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded.
Current or past head inject/ traumatic brain injury (TBI)
Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications.
History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well.
Potential participants who are unable to provide consent for the study.

What this trial measures

  • Collection of Ophthalmic Data1 Day

    Accuracy of the Gaize device in detecting eye-movement metrics consistent with prescribed psychotropic medication use, as determined by Drug Recognition Expert (DRE) testing protocols in a controlled virtual environment.